Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TODORA concentration-guided tocilizumab dose reduction trial in rheumatoid arthritis
NL-OMON52409Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Jan van Breemen Institute. Primary endpoint: Mean time-weighted DAS28-ESR at 28 weeks. Started Apr 2020; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON52409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52409.